Passage Bio, Inc. (PASG)

Market Cap	55.49M
Revenue (ttm)	n/a
Net Income (ttm)	-127.65M
Shares Out	54.63M
EPS (ttm)	-2.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,053
Open	1.01
Previous Close	1.00
Day's Range	0.99 - 1.04
52-Week Range	0.95 - 2.89
Beta	0.99
Analysts	Strong Buy
Price Target	8.80 (+766.4%)
Earnings Date	May 11, 2023

About PASG

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the br...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 28, 2020
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: PASG

Analyst Forecast

According to 5 analysts, the average rating for PASG stock is "Strong Buy." The 12-month stock price forecast is $8.8, which is an increase of 766.40% from the latest price.

Price Target

$8.8

(766.40% upside)

Analyst Consensus: Strong Buy